Eikon Therapeutics Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
The new data show that EIK1001 was well-tolerated with a manageable safety profile, and showed encouraging preliminary efficacy across several tumor types in combination with pembrolizumab.
- The new data show that EIK1001 was well-tolerated with a manageable safety profile, and showed encouraging preliminary efficacy across several tumor types in combination with pembrolizumab.
- Anthony W. Tolcher, MD, FASCO, of New Experimental Therapeutics (NEXT), will deliver the presentation on June 2, 2024 at 12:42 PM CDT.
- “We are encouraged by the promising data emerging from our lead clinical programs,” said Roy D. Baynes, MB.BCh., Ph.D., Chief Medical Officer of Eikon Therapeutics.
- Eikon will also host a booth in the exhibition hall (#32116) at the 2024 ASCO Annual Meeting.